Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting System
- 382 Downloads
Apparent elevations in reporting of amyotrophic lateral sclerosis (ALS)-like conditions associated with statin use have been previously described from data obtained via US and European databases.
The aim of this study was to examine US FDA Adverse Event Reporting System (FAERS) data to compare reporting odds ratios (RORs) of ALS and ALS-like conditions between statins and other drugs, for each statin agent.
We assessed for disproportional rates of reported ALS and ALS-related conditions for each statin agent separately by using the ROR formula. FAERS data were analyzed through September 2015.
RORs for ALS were elevated for all statins, with elevations possibly stronger for lipophilic statins. RORs ranged from 9.09 (6.57–12.6) and 16.2 (9.56–27.5) for rosuvastatin and pravastatin (hydrophilic) to 17.0 (14.1–20.4), 23.0 (18.3–29.1), and 107 (68.5–167) for atorvastatin, simvastatin, and lovastatin (lipophilic), respectively. For simvastatin, an ROR of 57.1 (39.5–82.7) was separately present for motor neuron disease.
These findings extend previous evidence showing that significantly elevated ALS reporting extends to individual statin agents, and add to concerns about potential elevated occurrence of ALS-like conditions in association with statin usage.
Compliance with Ethical Standards
This study had no funding source.
Conflict of interest
Alexis K. Messner and Hayley J. Koslik declare they have no conflict of interest and their efforts on this were unfunded. Beatrice A. Golomb is the executor of an estate (and will be among the beneficiaries) that includes some stock in drug companies that make statins. The estate lawyer has advised no changes be made to the portfolio until after distribution. Her effort on this project was unfunded. Keith B. Hoffman is a past employee of Advera Health Analytics, Inc. and is a stockholder and stock option holder in the company. Abril Verden is a current employee of Advera Health Analytics, Inc. and is a stock option holder in the company.
- 1.Reinberg S. New guidelines may widen use of statins: recommendations focus on patient risk factors rather than cholesterol numbers, experts say. WebMD.com. 2013. http://www.webmd.com/cholesterol-management/news/20131112/heart-experts-warn-against-crash-diets. Accessed 30 Oct 2017.
- 2.Szabo L. New heart guidelines could put more Americans on statins. USA Today. 2013. http://www.usatoday.com/story/news/nation/2013/11/12/new-heart-guidelines-cholesterol-statins/3489491/. Accessed 30 Oct 2017.
- 3.NICE publishes new draft guidelines on statin use. NHS Choices. 2014. http://www.nhs.uk/news/2014/02February/Pages/NICE-publishes-new-draft-guidelines-on-statins-use.aspx. Accessed 30 Oct 2017.
- 4.Hope J. One in four adults to be prescribed daily statins: now patients with 10% heart attack risk will be offered drug. Daily Mail. 2014. http://www.dailymail.co.uk/health/article-2557258/One-four-adults-prescribed-daily-statin-Now-patients-10-heart-attack-risk-offered-drug.html. Accessed 30 Oct 2017.
- 6.Golomb BA, Koperski S. Who becomes weak on statins? Effect modification exposed in a RCT by risk factor compounding. Circulation. 2013;127:AP072.Google Scholar
- 15.Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin. Clin Chem. 1992;38:504.Google Scholar
- 45.Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009;32:649–61.CrossRefPubMedGoogle Scholar
- 53.FDA. FDA Adverse Event Reporting System (FAERS): latest quarterly data files. 2015.Google Scholar
- 55.MedDRA. Medical dictionary for regulatory activities and the maintenance and support services. 2015. http://www.meddra.org/. Accessed 30 Oct 2017.
- 68.Kolata G. When drugs cause problems they are supposed to prevent. New York Times. 2010; October 16. http://www.nytimes.com/2010/10/17/health/policy/17drug.html. Accessed 30 Oct 2017.
- 69.Golomb B. Effect modification. What scientific term or concept ought to be more widely known. Edge.org. 2017. https://www.edge.org/response-detail/27223. Accessed 30 Oct 2017.
- 70.Food and Drug Administration. FDA Public Health Advisory on Crestor (rosuvastatin). FDA.gov. 2005. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051756.htm. Accessed 30 Oct 2017.
- 88.AHRQ. The Medical Expenditure Panel Survey (MEPS). Meps.ahrq.gov. 2015. https://meps.ahrq.gov/mepsweb/. Accessed 30 Oct 2017.
- 89.EvaluatePharma. USA sales, volume and price analysis. EvaluateGroup.com. 2014; Version 1.8. http://www.evaluategroup.com/pdf/EvaluatePharma-USA-SVP-Methodology.pdf. Accessed 30 Oct 2017.